This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Good afternoon and welcome everyone to the GeoVax fourth quarter year-end 2021 corporate update call. I am Chuck with Coors Call and will facilitate today's call. With me are David Dodd, Chairman and CEO, Mr. Mark Reynolds, Chief Financial Officer, Mark Newman, PhD, Chief Scientific Officer, and John Sharkey, PhD and Head of Business Development. All participants will be in a listen-only mode should you need assistance Please signal a conference specialist by pressing the star key, followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mr. Jules Abraham of CORE-IR, who will provide a forward-looking statement regarding the call and the information herein. Please go ahead, sir.
spk01: Thank you, Chuck. Good afternoon, everyone. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GLS can develop and manufacture its vaccines with the desired characteristics in a timely manner, whether Geovax's vaccines will be safe for human use, whether Geovax's vaccines will effectively prevent targeted infections in humans, whether Geovax's vaccines will receive regulatory approvals necessary to be licensed and marketed, whether Geovax raises required capital to complete vaccine development, and there is development of competitive products that may be more effective or easier to use than Geovax's products. whether Geovax will be able to enter into favorable manufacturing and distribution agreements and other factors over which Geovax has no control. Geovax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in Geovax's filings with the Securities and Exchange Commission, including those set forth at risk factors in Geovax's Form 10-K. With that, it's now my pleasure To introduce the Chairman and CEO of U of X, David Dodd. David.
spk05: Thank you, Jules. Good afternoon, and thank you for participating in the 2021 fourth quarter year-end update call. We're pleased to have this opportunity to review our successful acceleration to phase two clinical development within COVID-19 and immuno-oncology while we continue to secure critical resources in support of GEOVAC's growth and development while advancing our IND-enabling programs. Over the past year, we utilized our balance sheet to catapult into Phase II clinical development through the strategic in-licensing of both GEO CMO4S1 and GADEPTIN. CMO4S1, which we in-licensed exclusive global rights from City of Hope National Medical Center, is a next generation COVID-19 vaccine targeting both antibody and cellular immunity with the goal of providing more robust and durable protection than the current authorized vaccines. Gideptin is a cancer immunotherapy, which we analyze since exclusive global rights from PMP Therapeutics and the University of Alabama, Birmingham, currently being evaluated among patients suffering from advanced head and neck cancers that has received orphan drug status from the FDA. In addition, we're advancing encouraging internal programs on the path to IND filings. In January, we issued a 2021 milestone report addressing the goals we established and communicated early last year. Entering 2021, we built a strong balance sheet supporting both strategic transactions and an organization with the expertise to accelerate our growth and development. We successfully executed our plans, propelling our status into phase two clinical development within both COVID-19 and immuno-oncology. In addition, we advanced our internal programs within COVID-19 and immuno-oncology, as well as reported encouraging results in support of our hemorrhagic fever virus vaccine program. This included a scientific presentation at the 2021 World Vaccine and Immunotherapy Congress in early December. validating our COVID-19 vaccine approach of a multi-antigenic vaccine eliciting strong antibody and cellular immune responses, potentially providing more robust and durable protection beyond the current authorized vaccines, which are primarily designed to induce neutralizing antibodies. In fact, in a well-validated lethal challenge transgenic mouse model, our CMO2 candidate, which is the first step towards a universal coronavirus vaccine, provided complete protection following a single dose, even in the absence of measurable neutralizing antibodies. To our knowledge, these results are unprecedented. I'll note that both our phase two COVID-19 vaccine, CM04S1, and our CM02, both are multi-antigenic COVID-19 vaccines designed to strongly elicit both antibody and cellular immune responses. At that same scientific congress, We also reported further encouraging results in support of our Marburg and Sudan vaccines. During this year, we anticipate reporting milestones and progress related to both our clinical and IND enabling programs. So let's move into further discussion related to our exciting programs and activities underway at GFS. As we enter this year, we further strengthened our balance sheet while focusing on the acceleration of our CM04S1 in Gidepton Phase II programs in completing the IND enabling activities in support of our CMO2 vaccine for COVID-19, our Mach 1 vaccine in immune oncology, and our hemorrhagic fever virus vaccines, the latter of which are supported via non-diluted funding and activities. In addition, we have further enhanced our resources and expertise in support of successfully executing upon our 2022 and beyond plans for growth and development of the company. Our priority focus this year is to accelerate the recruitment and enrollment of our three Phase II programs. This includes our multi-site clinical trial in support of GADEPTIN and our two clinical trials in support of CM-04S1. Since our recent GADEPTIN announcement, we have confirmed two additional clinical sites in the assignment of CatoSMS as our CRO partner responsible for leading the expansion and acceleration of the Cadeptan Clinical Program. Our goal is to complete patient enrollment towards the end of 2022 or early 2023, followed by completion of patient evaluations by the end of 2023. Should the results be supportive, a BLA filing will likely shortly happen thereafter. In parallel with the ongoing clinical program, we're also engaged with a CDMO to prepare for commercial manufacture. We are confident that the Godeptin Phase II program will be successfully managed by CatoSMS and our clinical operations team with this possible expansion of further additional clinical sites soon. We're highly excited about the outlook and promise of Godeptin within advanced head and neck cancer, where it has received orphan drug designation from the FDA and has previously provided encouraging potential for such patients. In addition, there are promising opportunities relative to expanded use of cadeptin and other indications, as well as the GDEP technology in conjunction with other therapies and potential synergy with our MVA-VLP, tumor-associated antigen approach. We're looking forward to providing milestone updates throughout this year about the progress of our cadeptin program. In November of last year, we announced exclusive worldwide license of a phase two COVID-19 vaccine from City of Hope National Medical Center. This exciting vaccine is now referred to as GEO CM04S1, which I typically refer to as CM04S1. CM04S1 utilizes synthetic modified vaccinia anchor or MVA technology similar to our other vaccine programs under development at GeoVax. This transaction literally propelled us into a critical stage of clinical development. CM04S1 works by inducing immunity to SARS-CoV-2 by stimulating the immune system to produce antibodies against SARS-CoV-2 that can block the virus from entering healthy cells while the immune system can also grow new disease-fighting T cells that can recognize and destroy infected cells. The vaccine includes both SARS-CoV-2 spike and nuclear capsid proteins. By inserting these proteins, the MVA delivery vehicle is able to drive the expression of both proteins within the body of the vaccine recipient, inducing immune responses. The role of the S protein is to elicit a neutralizing antibody response against the initial infection, while the M protein elicits a T cell response to directly attack virus-infected cells, reduce viral replication, and reduce severity and clearance. Thus, the vaccine is designed to induce both neutralizing antibodies and T cell responses specific for the S protein and the M protein. This vaccine design was implemented specifically to induce an expanded immune response to better combat and clear infections regardless of the circulating SARS-CoV-2 variants. Our goal is to provide a vaccine that gets ahead of the variants versus having to chase the variants, which if successful, will reduce reliance on the repeated administration of booster doses of existing vaccines. Frankly, we believe that such a multi-punch approach has the potential for providing more robust and durable immune response and protection than the current authorized vaccines. We also believe that various high-risk populations such as immune compromised individuals will greatly benefit from such a two-prong approach. CMO4S1 is currently being evaluated in two phase two clinical trials. One trial is the first comparative trial of an investigative COVID-19 vaccine with the current FDA approved Pfizer vaccine and people that have received or are undergoing specific blood cancer therapies associated with transplantation or CAR T therapy that suppress or severely reduce preexisting immunity to COVID-19 vaccine. Multiple clinical trials have demonstrated that such patients fail to respond optimally to the current generation vaccine. And we believe that CM04S1 will prove to be more potent because it is multi-antigenic and delivered using the MVA vector. We believe this will differentiate CM04S1 from the other vaccines by providing both a strong antibody response and a sustained T cell response in these patients who are still at high risk due to their immunocompromised status of severe COVID-19. The other trial currently underway is evaluating CMO4S1 as a booster for healthy patients who have previously received either the Pfizer or Moderna mRNA vaccines. We believe that providing a heterologous booster rather than a third or fourth shot of the same vaccine may provide more robust and durable immune response and protection. Heterologous prime boost immunizations are well studied in other fields, such as HIV. and are being evaluated in multiple countries using different COVID vaccines. We are working with Cato, SMS, and Pharmalon following their recent merger to oversee the acceleration and management of these two exciting clinical programs, working in conjunction with our internal clinical operations team. Finally, the ongoing GFX effort to develop a manufacturing process based on a continuously growing avian cell line to increase production consistency and capacity will mesh with the clinical development activities and full development schedule associated with the CM04S1 and the CMO2 vaccines. The potential benefits of this transaction to the G of X program are highly significant and timely. Now, I'd like to turn the presentation over to Mark Reynolds, G of X Chief Financial Officer, for a review of our recent results and financial statements. Mark?
spk04: Thank you, David. So starting with our income statement, grant collaboration revenues were down to 385,021 versus 1.8 million in 2020. And that's the 21 period revenues relate entirely to our grant from NIH for our COVID-19 vaccine for the pan-coronavirus program. While the 2020 amount includes revenues from our grant from the U.S. Army supporting our loss of fever vaccine program, which had begun to wind down during that period. That's the reason for the reduction. Research and development expenses were $15.6 million in 21 versus $2.4 million in 2020, with the increase primarily associated with our license fees, both paid and accrued, and clinical trial expenses related to our license agreement with City of Hope for the COVID-19 vaccine program, as well as for our license cadets. Also contributing to the increase were expenses related to our universal coronavirus vaccine program, manufacturing process development, and generally a higher level of activity. G and A expenses were 3.6 million in 21 versus 2.2 million in 2020. A large portion of the increase here was related to our annual Delaware franchise tax, which is based on our capitalization and was minimal during 2020. Other increases in insurance premiums, patent costs, legal fees, consulting fees, and personnel costs are generally associated with preparing our organization for a higher level of activity following capital raises. Other income and expense for 21 included $172,000 gain on extinguishment of debt associated with the forgiveness of PPP loan we received in early 2020. A comparable figure for 2020 includes interest expense of $144,000 related to convertible ventures that were retired during that year. So overall net loss for 21 was $18.6 million, or $3.04 per share, versus $3 million in 2020, or $2.14 per share, again with the increase primarily associated with our licensing and R&D activities. Turning now to the balance sheet, our cash balances at the end of this past year were $11.4 million as compared to $9.9 million at the end of 2020. The change in cash balances is reflective of approximately $11 million used in operating income, all set by proceeds from our stock offering in early 21, which generated net proceeds to us of $9.4 million. During the year of 2021, we also received $3.4 million from the exercise of our publicly traded warrants. Subsequent to year end, in January of this year, 2022, we raised an additional $9.2 million through private placement priced at $3.26 per share. So as of today, GeoVax has cash balances of approximately $17 million. Now that we've got three ongoing Phase II clinical programs in COVID-19 and cancer immunotherapy, our cash needs have obviously increased, not only for license fees and direct costs associated with clinical programs, but also for the facilities, personnel, and other costs to support those programs. And while we don't provide specific forward-looking estimates of costs to complete these programs, what we can say at this time is that our existing cash resources are sufficient to fund our operations and our current business plan priority programs into the second quarter of 2023. We believe the advancement of these programs will create an attractive investment opportunity for new fundraising opportunities as they present themselves. And I'll be happy to answer any questions during the Q&A, and I'll now turn the call back over to David.
spk05: Thank you, Mark. My colleagues and I will now answer your questions. Joining us for the Q&A session are doctors Mark Newman and John Sharkey, our chief scientific officer and head of business development respectively. I'm therefore turning the call over to the operator for instructions on the Q&A period.
spk06: We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. And to withdraw your question, please press star then two. And at this time, we'll pause momentarily to assemble our roster. And the first question will come from Jason McCarthy with Maxim Group. Please go ahead.
spk07: Hi, guys. Thanks for taking the questions. Let's start with the 04-S1 program. And maybe any of you could speak a little bit more broadly about the state of COVID vaccines and the pandemic now because the data that we were seeing on the mRNA side with Omicron was less than fantastic or desirable like we saw with Delta and some of the other variants and you and I both know that it's not the last letter in the Greek alphabet there probably will be more variants we'll probably be looking at something again surging next year so it's So the Omicron data, does that change the importance now of O4S1 and the need for doing something different than just mRNA?
spk05: Thank you, Jason. This is David Dodd. I'll start and then I'll ask Mark Newman to pick up. And I'd say that we share your outlook for how there will continue to be emerging variants. We can't predict what letters of the alphabet they'll be and what their constructs will be. But clearly, there is a need for other than mRNA vaccines that are out there. So the current authorized vaccines in a number of matters are insufficient, and especially among high-risk populations, those who have compromised immune systems. We know that they are being highly insufficiently served by the existing vaccines. But in general, we need additional ones so that we can, as we refer to it, get ahead of the variants and be able to strongly elicit both antibody as well as the T cells to be able to provide better protection, more robust and durable protection. But I'll ask Mark Newman to pick up from here. Mark?
spk03: Yeah, sure. Thanks. So, I think what you're seeing, we've seen the world start to recognize is that targeting the S protein alone and focusing on neutralizing antibodies have some limitations. So this is impacting primarily the vaccines that are based on just the receptor binding domain, right, that part that interacts and, you know, mediates the infection into a cell. Now, that is not the current generation mRNA vaccines. They're total S proteins. So But that's still, the mutations are mutating around the receptor binding domain primarily. We just had a World Health Organization conference a couple weeks ago, which I participated in. And, you know, it's interesting because the new variants, while they're not being protected as well with the current generation of vaccines, The immune responses they're generating don't protect against previous infections as well. So it's almost like the virus can go first full circle. And that was actually the way it was described. They actually come back to where it started. And of course, you don't have long-lived immunity, one of the issues that's being pointed out with the mRNA vaccine. So I've been saying for a year now that we need to have a broader response. We need to focus on T cell responses to the conserved Structural proteins, these are the things that make a coronavirus a coronavirus. There's conserved regions in the S protein, but also the M and the nucleocapsid, which are in the CMO2 and the O4S1, respectively. And so the world is starting to come to realize that. The difficulty is, while everyone accepts it, how do you measure it and how do you design a vaccine? Heterologous prime boosts are back in vogue. Those of you who followed HIV vaccine work for decades will remember that there was multiple attempts to boost immune responses by using different product formats. Now you're hearing about what they call mix and match. If you got the J&J vaccine, go get a different one. Go get one of the mRNA. If you got an mRNA, you can boost it with the J&J or an AstraZeneca vaccine if you're living in Europe. And so those are the approaches that are being taken. Obviously, the evolution of variants drives the need for next generation products. But if you're holding one of the current generation products, you're going to try and find a way of using it. And you're seeing both of these aspects, you know, kind of float into the medical world. So, heterologous prime boost using existing vaccines and then next generation vaccines that are designed to induce a broader response. There is some interest in the mRNA field, in particular, in making Omicron. But by the time they made the Omicron vaccine and got it into phase one, the Omicron cousin was already out there. It was B1, now B2. And so chasing variants, as David said, is just not something that we feel is a logical approach. So does that answer your question?
spk06: Perhaps you're muted, Mr. McCarthy. Okay, to move on?
spk05: Yes, please.
spk06: Again, if you have a question, please press star, then 1. Our next question will come from Shubhendu Sinroy with Brookline Capital. Please go ahead.
spk00: Hi, I'm Shubhendu for Kumar from Brookline. Appreciate the update. Thank you. So with regards to the Sudan and Markburg programs, first of all, congratulations on encouraging preclinical data. My understanding is that the clinical trials would move with federal funding. So I was wondering if you have any inputs from the Department of Defense or USAID or BARDA regarding the clinical studies, and how are you thinking in terms of taking these programs further?
spk05: And you're specifically addressing the hemorrhagic fever, right? Yeah. Yes. Okay. Thank you. Thank you. I just wanted to make sure. Well, we currently, those programs have been supported through NIH preclinical services through non-human primate testing and all. And during the course of our progress with these products, you may be aware that we initially demonstrated for Ebola Zaire, our vaccine, showed 100% protection in a single dose without the use of any adjuvants. And I think that's unprecedented in non-human primate models to achieve that result in a single dose. And then we had moved forward with our current products also. In the course of all that, we have been and continue to be in dialogue with BARDA, about the Strategic National Stockpile Program and the progress of our products and the potential. You know, time will tell. We believe that with the progress we've seen and support through the non-human primates from NIH's preclinical services, that depending on the outcome, we would anticipate that if there is the opportunity to move it forward in the clinical development, we would more than likely be supported through non-diluted funding. And that's consistent with discussions that we've had on an ongoing basis. So, Mark, do you want to add anything?
spk03: Well, I can just add that the real world is that when COVID hit, you couldn't get non-human primates to do the testing. And so that slowed us down. But that has picked back up and everything is back on schedule. And we fully anticipate, we were analyzing data yesterday. So we're seeing all sorts of different results come in through these contracts. And we fully anticipate having a BARDA TechWatch meeting this year. We'll just have to see what the data looks like. But everything is back on track, just dealing with the shortage of test animals.
spk00: Great, thanks. This was helpful. Now, with regards to the pan-coronavirus CMO2 program that elicits both B and T cell responses in preclinical models, can you give some more color to your future plans? And are you planning to develop this for other coronaviruses like MERS?
spk03: Yes. So, again, remember that in MERS, it's a significantly different S protein, right? Some of it's the same as with COVID, but it's a it uses a different receptor. But the matrix, the nucleocapsid, the envelope, a lot of the non-structural proteins, like the enzymes and things that the virus uses to process proteins and DNA, those are all very highly shared amongst beta coronaviruses. And what we're doing is, it's an ongoing program, looking at other targets we can roll into the existing CMO2. So CMO2 is now basically the backbone because the O4S1 is fairly similar and that's in phase two trial. So we don't want to necessarily play a lot of games with that one. But the CMO2 is where we can start rolling these open reading frame proteins in that are highly conserved because they have enzymatic activity, other structural and non-structural proteins. And we're making those. We have a next generation, product is, you know, being sequenced right now to see if it's holding up and looks like we want. And that's a, you know, the program that we pitched and discussed with, you know, groups like CEPI and the NIH involve, again, shifting away from the S protein and reliance on neutralizing antibodies, not that we wouldn't have S protein, but expanding it. And all this is rolling along. It's all in in either in the construction phase or it goes into small animal models, you know, at first. So it's on track. It was always an extended, you know, two to four-year program depending on, you know, where we are successful and how the world has evolved. We can rely a little bit on what people are seeing in the human population as people recover. you can measure their immune response and determine what genes should also be targeted. A lot of that work is done out of the La Jolla Institute in San Diego. And so we're now using that to continually guide our process into what would the next CMO2 look like? What else would we add? So that's still going, but it's separate and it's more research focused from the O4S1. which is targeting the existing pandemic and the immunocompromised patients. So the CMO2 is really the beta coronavirus vaccine of the future. That's how we're looking at that.
spk05: I would just add that we, you know, I was going to say our plan is to drive through the clinical development 04S1 because we believe that it can more immediately address populations that are highly at risk, that are not being adequately protected with the current vaccines, and then that we can follow along with an even further development that will give greater protection going forward as we see coronaviruses continue to evolve.
spk00: Yeah, that makes sense, yeah. Just one final question with regards to the cancer vaccine program. Do you plan non-human primate studies for the MVA VLP MUC1 program? What kind of data do you think will be sufficient to get it into the clinic now? Thanks.
spk03: For the cancer programs, no. We don't envision going into non-human primates. Those are typically handled through transplantable tumor models. And so we just initiated another trial, another animal experiment using human transgenic mice for the MUC1 program, a well-established model. And so there, what you do is you vaccinate and challenge with the tumor by transplanting the tumor in. Or you transplant the tumor in first, and then you start vaccinating and see if you can retard tumor growth. So that's the type of study that's done for those. there's no transplantable tumors you could use for the non-human primates. And you can't just sit around and wait and see if they get cancer. So those are under control that way. The path forward that we're taking is we're piggybacking on other programs, what others have done involving the MUC1 gene. So there's a significant history about targeting immune responses against apparently glycosylated MUC1. And it's a situation where your body raises immune responses on its own sometimes to the adenocarcinomas. And so these have been, there are products that have been tested in clinical trials through one of our collaborators, University of Pittsburgh. And so this is how we'll be moving this. The goal is to take something that's already been in a phase one or phase two trial, and then add the MVA to that. So you're looking at two experimental products, but two experimental products that have a great deal of safety and initial evaluation behind them. And that's what will allow us to put them together through an FDA-approved study. But no non-human primates. That's just not something we do for cancer.
spk00: Okay, great. Thank you for taking my questions. No problem.
spk06: The next question will come from Jason McCarthy with Maximum Group. Please go ahead.
spk07: Hey, guys. Sorry, I got cut off. I think a lot of my COVID-related questions were subsequently answered, but I wanted to touch on the GADEPTIN program. We think it's really important. Can you give us an update on where those first 10 patients are in terms of enrollment or their progress? And then what are the expectations in terms of how many patients you think you might have to add for this program to make it registrational? And the third part to that question is, you know, what would be considered a good objective response rate in a second line having that cancer? Would it be 10%, 20%, 30%? And what do you think would be clinically meaningful for this program?
spk05: Thank you. Let me ask, John Sharkey, would you like to answer that?
spk02: Sure, sure. As last I recall, there have been five patients enrolled. There's two patients who are being screened for enrollment, and so that would be seven of the ten. The The expansion of the trial to basically make a registration, we are currently, our thinking is in the range of 30 patients for the additional trial on top of the 10, looking at a different dose, a higher dose of the drug to maximize the effect. And as far as what sort of increase would he think, This is going to be personal opinion at this point. We are putting this stuff together to initiate a discussion with the agency on this. But I would imagine it would probably be in the range of 20 to 30% against current standard of care because this would be for an end stage. But that's purely, I'd have to say, speculation at this point until we have that discussion with the agency. Hopefully that answers your question, Jason.
spk07: Yeah, it does. Thank you. You know, if you're successful with a 20% to 30%, whatever the response rate that you're going to need, that was your view, it's not what the FDA has said just yet, would it be optional to then move to first line for a trial? We've seen that with a few other programs out there. Burke is doing this with another group. for a combination study. The data looked so good and, you know, one cohort of a second-line head and neck program that they immediately went to a first-line program. That was the interaction with regulators. That was the outcome. Is that something that the GADEPTIN program could follow, kind of on a similar path to that?
spk02: For head and neck, given its mechanism of action, As a single agent, I personally don't think it would likely move into first line. However, as we've also said, we're looking at it early on with combination with checkpoint inhibitors. And the data suggests that you improve the response of metastatic disease to checkpoint inhibitors. This is an animal model when you use Gidefin. That potentially could move up into an earlier stage treatment paradigm in combination with checkpoint inhibitors in certain patient populations. That I could see happening. I just don't, in my personal opinion, given this mechanism of action in end-stage disease, I think people would try other treatment paradigms first as a standalone age.
spk07: And lastly, is the expectation, and you haven't not met with regulators yet that it would only be about 30 people that you have to add. Some of the one-sided trials that we've seen for approvals, they've ranged, right, from anywhere as low as 30 to as high as 150 people to gain or to be sufficient for filings. Is it possible that they could want more than 30, even less than 30? We've seen some sarcoma studies where they'll take like 15, 20 people, and that's more than enough given the unmet needs.
spk02: In dealing with the agency, anything is possible. But that's the reality. But given that this is an end-stage disease and they have no other treatment options the way the trial was designed, that it's most likely I would expect to be on the lower end of the range of what would be you would see for these types of trials. It's just that it is an end-stage case.
spk05: Yeah, I would add, Jason, that based upon the discussion that was held with the agency following the Phase I program, the indication was given that a number of patients in the current Phase II trial lower than what we have. We're exceeding it by more than They were looking for something more like 20 in total. And we're looking at adding potentially 30 on top of the 10, so that would be almost double the number. And they were looking for that as a minimal number. So what we have invested in and what we're investing in is to increase the number basically significantly beyond the number that had previously been indicated. but to also engage in discussions as we add these additional sites and expand beyond that and accelerate the enrollment, which is what we're focused on for this year. But we do believe we will end up completing more than the number of patients that have previously been indicated.
spk07: Great.
spk06: Thank you for taking the questions.
spk05: Thank you.
spk06: This concludes our question and answer session. I would like to turn the conference back over to Mr. David Dodd for any closing remarks. Please go ahead.
spk05: Thank you. And thank you, everyone, for participating in this conference call, sharing in our milestone achievements resulting in clinical stage development within both immuno-oncology.
spk06: Pardon me. It seems that Mr. David Dodd has disconnected. Would someone else like to give closing remarks?
spk04: I'll finish it off by just saying thanks to everybody participating and hope everybody has a pleasant evening.
spk06: The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.
Disclaimer